Clinical Results of Selinexor Combo Regimen for Multiple Myeloma Presented by Moffitt Cancer Cancer at ASCO 2016
The Moffitt Cancer Center has completed a Phase 1 clinical trial of selinexor combined with liposomal doxorubicin and dexamethasone for the treatment of relapsed and refractory multiple myeloma (MM) patients. The results of the trial were presented June 6 in Chicago at the 2016 Annual Meeting of the…